EGFR and cancer: The ability of quinazoline-containing 1,2,3-triazole compounds to modulate the expression of genes involved in VEGFR-2, EGFR, and mTOR signaling suggests that these novel agents may have the potential to overcome the limitations of existing VEGFR-2 inhibitors and provide a more comprehensive approach to cancer treatment22.